+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

HIV Drugs Market Analysis & Forecast to 2024-2034

  • PDF Icon

    Report

  • 200 Pages
  • January 2024
  • Region: Global
  • Erevna Healthcare
  • ID: 5923109
The global HIV drugs market size was estimated to be USD 34.26 billion in 2023 and is expected to reach at USD 64.83 billion by 2034 with a CAGR of 5.97% during the forecast period 2024-2034. The surge in the demand for HIV medications, escalating initiatives from diverse government entities to promote awareness regarding the diagnosis and management of HIV, an increase in HIV cases, heightened awareness about HIV driving more individuals toward testing and diagnosis, an upswing in funding from international programs and organizations aimed at raising awareness and alleviating the burden of HIV, and a growing investment in research and development endeavors to enhance comprehension of HIV's underlying mechanisms & devise innovative therapies, and the upsurge in research and development activities in drug discovery are some of the key factors boosting the market growth.

The upsurge in research and development activities in drug discovery is predicted to boost the market growth during the forecast period. This involves the exploration of novel drug targets, the undertaking of clinical trials, and the examination of combination therapies. For instance, in February 2023, Merck, also recognized as MSD outside the United States and Canada, has declared the initiation of enrollment in its latest Phase 3 clinical initiative. This program involves the investigation of the investigational once-daily islatravir 0.25 mg in conjunction with doravirine 100 mg (DOR/ISL) for treating HIV-1 infection.

By medication class, multi-class combination drugs was the highest revenue-grossing segment in the global HIV drugs market in 2023 owing to the widespread utilization of combination drugs encompassing multiple classes in HIV treatment, the efficacy of these multi-class combinations against HIV, and the increasing endorsement of such combination drugs. For instance, in December 2022, Gilead Sciences, Inc. reported that the U.S. Food and Drug Administration (FDA) has approved Sunlenca (lenacapavir) in combination with other antiretroviral(s) (ARV) for treating HIV-1 infection in heavily treatment-experienced (HTE) adults with multi-drug resistant (MDR) HIV-1 infection. Additionally, HIV integrase strand transfer inhibitors is predicted to grow at fastest CAGR during the forecast period as it is recommended as primary treatment for HIV and the continuous introduction of new drugs, this combination represents a significant advancement in HIV therapy.

By distribution channel, hospital pharmacies was the highest revenue-grossing segment in the global HIV drugs market in 2023 owing to the substantial drug sales originating from hospital pharmacies, the elevated count of HIV patients seeking treatment at hospital facilities, and surge in market approvals by regulatory bodies. For instance, in February 2023, ViiV Healthcare, a subsidiary of GlaxoSmithKline plc, declared that the European Commission has approved Marketing Authorization for Triumeq. This approval pertains to a dispersible tablet version of the fixed-dose combination of abacavir, dolutegravir, and lamivudine, designed for treating pediatric patients weighing between 14 kg to 25 kg with human immunodeficiency virus type 1 (HIV-1). Additionally, online pharmacies is predicted to grow at fastest CAGR during the forecast period owing to the ease of shopping, growth in online sales, advancements in logistics, and simplified payment choices contribute to the accessibility and substantial discounts and offers offered by these digital platforms.

North America region is anticipated for the highest revenue share during the forecast period owing to the increase in the quantity of clinical trials for HIV medications, the presence of advanced healthcare facilities, substantial healthcare funding from governmental entities, the presence of an intricate reimbursement system designed to lower expenditure, and the rising number of approvals from regulatory bodies. For instance, in March 2022, Janssen Pharmaceutical, a fully owned subsidiary of Johnson & Johnson, reported that the U.S. Food and Drug Administration (FDA) granted approval for CABENUVA (cabotegravir and rilpivirine) to treat HIV-1 in adolescents who have achieved virological suppression. Developed in collaboration with ViiV Healthcare, CABENUVA stands as the initial and sole comprehensive long-acting treatment regimen for HIV-1. Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the existence of major contributors, an upswing in research and development endeavors focused on HIV medications, an increase in the demand for HIV drugs, a growing population coupled with extended life expectancy, and an uptick in regulatory approvals for innovative products. For instance, in May 2022, ViiV Healthcare, a branch of GlaxoSmithKline plc, disclosed that it received approval from the Ministry of Health, Labor and Welfare (MHLW) in Japan for Vocabria (cabotegravir injection and tablets). This approval is for its combination with Janssen Pharmaceutical Companies' Rekambys and Edurant from Johnson & Johnson, marking the initial and exclusive comprehensive long-acting treatment for HIV in Japan.

Segmentation: HIV Drugs Market Report 2023 - 2034

HIV Drugs Market Analysis & Forecast by Drug Class 2023 - 2034 (Revenue USD Bn)

  • Entry Inhibitors
  • Selzentry
  • Fuzeon
  • Rukobia
  • Multi-Class Combination Drugs
  • Atripla
  • Complera
  • Prezcobix
  • Stribild
  • Genvoya
  • Odefsey
  • Symtuza
  • Triumeq
  • Descovy
  • Dovato
  • Others
  • Protease Inhibitors (PIS)
  • Aptivus
  • Kaletra
  • Lexiva/ Telzir
  • Norvir
  • Viracept
  • Others
  • Nucleoside Reverse Transcriptase Inhibitors (NRTIS)
  • Emtriva
  • Epivir
  • Epzicom
  • Truvada
  • Biktavry
  • Others
  • HIV Integrase Strand Transfer Inhibitors
  • Isentress
  • Tivicay
  • Apretude
  • Juluca
  • Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIS)
  • Edurant
  • Others
  • Others

HIV Drugs Market Analysis & Forecast by Distribution Channel 2023 - 2034 (Revenue USD Bn)

  • Hospital Pharmacies
  • Drugs Stores & Retail Pharmacies
  • Online Pharmacies

HIV Drugs Market Analysis & Forecast by Region 2023 - 2034 (Revenue USD Bn)

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • France
  • UK
  • Spain
  • Italy
  • Rest of Europe
  • Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Rest of LATAM
  • Middle East & Africa
  • South Africa
  • GCC
  • Rest of MEA

Table of Contents

1. Research Methodology
1.1. Study Objectives
1.2. Study Scope
1.3. Research Assumptions
1.4. Research Framework
2. Introduction
2.1. Market Definition
2.2. Global HIV Drugs Market Overview
3. Executive Summary
4. Market Environment Analysis
4.1. Porter’s 5 Forces Analysis
4.2. PESTEL Analysis
4.3. SWOT Analysis
5. Market Dynamics
5.1. Drivers Analysis
5.2. Restraints Analysis
5.3. Opportunities Analysis
5.4. Threats Analysis
5.5. Trend Analysis
6. COVID-19 Impact Analysis
7. HIV Drugs Market: Drug Class Estimates & Trend Analysis
7.1. Drug Class Segment Opportunity Analysis
7.2. Entry Inhibitors
7.2.1. Entry Inhibitors Market Analysis & Forecast, 2023-2034 (Revenue, USD Bn)
7.2.2. Selzentry
7.2.2.1. Selzentry Market Analysis & Forecast, 2023-2034 (Revenue, USD Bn)
7.2.3. Fuzeon
7.2.3.1. Fuzeon Market Analysis & Forecast, 2023-2034 (Revenue, USD Bn)
7.2.4. Rukobia
7.2.4.1. Rukobia Market Analysis & Forecast, 2023-2034 (Revenue, USD Bn)
7.3. Multi-Class Combination Drugs
7.3.1. Multi-Class Combination Drugs Market Analysis & Forecast, 2023-2034 (Revenue, USD Bn)
7.3.2. Atripla
7.3.2.1. Atripla Market Analysis & Forecast, 2023-2034 (Revenue, USD Bn)
7.3.3. Complera
7.3.3.1. Complera Market Analysis & Forecast, 2023-2034 (Revenue, USD Bn)
7.3.4. Prezcobix
7.3.4.1. Prezcobix Market Analysis & Forecast, 2023-2034 (Revenue, USD Bn)
7.3.5. Stribild
7.3.5.1. Stribild Market Analysis & Forecast, 2023-2034 (Revenue, USD Bn)
7.3.6. Genvoya
7.3.6.1. Genvoya Market Analysis & Forecast, 2023-2034 (Revenue, USD Bn)
7.3.7. Odefsey
7.3.7.1. Odefsey Market Analysis & Forecast, 2023-2034 (Revenue, USD Bn)
7.3.8. Symtuza
7.3.8.1. Symtuza Market Analysis & Forecast, 2023-2034 (Revenue, USD Bn)
7.3.9. Triumeq
7.3.9.1. Triumeq Market Analysis & Forecast, 2023-2034 (Revenue, USD Bn)
7.3.10. Descovy
7.3.10.1. Descovy Market Analysis & Forecast, 2023-2034 (Revenue, USD Bn)
7.3.11. Dovato
7.3.11.1. Dovato Market Analysis & Forecast, 2023-2034 (Revenue, USD Bn)
7.3.12. Others
7.3.12.1. Others Market Analysis & Forecast, 2023-2034 (Revenue, USD Bn)
7.4. Protease Inhibitors (PIS)
7.4.1. Protease Inhibitors (PIS) Market Analysis & Forecast, 2023-2034 (Revenue, USD Bn)
7.4.2. Aptivus
7.4.2.1. Aptivus Market Analysis & Forecast, 2023-2034 (Revenue, USD Bn)
7.4.3. Kaletra
7.4.3.1. Kaletra Market Analysis & Forecast, 2023-2034 (Revenue, USD Bn)
7.4.4. Lexiva/ Telzir
7.4.4.1. Lexiva/ Telzir Market Analysis & Forecast, 2023-2034 (Revenue, USD Bn)
7.4.5. Norvir
7.4.5.1. Norvir Market Analysis & Forecast, 2023-2034 (Revenue, USD Bn)
7.4.6. Viracept
7.4.6.1. Viracept Market Analysis & Forecast, 2023-2034 (Revenue, USD Bn)
7.4.7. Others
7.4.7.1. Others Market Analysis & Forecast, 2023-2034 (Revenue, USD Bn)
7.5. Nucleoside Reverse Transcriptase Inhibitors (NRTIS)
7.5.1. Nucleoside Reverse Transcriptase Inhibitors (NRTIS) Market Analysis & Forecast, 2023-2034 (Revenue, USD Bn)
7.5.2. Emtriva
7.5.2.1. Emtriva Market Analysis & Forecast, 2023-2034 (Revenue, USD Bn)
7.5.3. Epivir
7.5.3.1. Epivir Market Analysis & Forecast, 2023-2034 (Revenue, USD Bn)
7.5.4. Epzicom
7.5.4.1. Epzicom Market Analysis & Forecast, 2023-2034 (Revenue, USD Bn)
7.5.5. Truvada
7.5.5.1. Truvada Market Analysis & Forecast, 2023-2034 (Revenue, USD Bn)
7.5.6. Biktavry
7.5.6.1. Biktavry Market Analysis & Forecast, 2023-2034 (Revenue, USD Bn)
7.5.7. Others
7.5.7.1. Others Market Analysis & Forecast, 2023-2034 (Revenue, USD Bn)
7.6. HIV Integrase Strand Transfer Inhibitors
7.6.1. HIV Integrase Strand Transfer Inhibitors Market Analysis & Forecast, 2023-2034 (Revenue, USD Bn)
7.6.2. Isentress
7.6.2.1. Isentress Market Analysis & Forecast, 2023-2034 (Revenue, USD Bn)
7.6.3. Tivicay
7.6.3.1. Tivicay Market Analysis & Forecast, 2023-2034 (Revenue, USD Bn)
7.6.4. Apretude
7.6.4.1. Apretude Market Analysis & Forecast, 2023-2034 (Revenue, USD Bn)
7.6.5. Juluca
7.6.5.1. Juluca Market Analysis & Forecast, 2023-2034 (Revenue, USD Bn)
7.7. Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIS)
7.7.1. Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIS) Market Analysis & Forecast, 2023-2034 (Revenue, USD Bn)
7.7.2. Edurant
7.7.2.1. Edurant Market Analysis & Forecast, 2023-2034 (Revenue, USD Bn)
7.7.3. Others
7.7.3.1. Others Market Analysis & Forecast, 2023-2034 (Revenue, USD Bn)
7.8. Others
7.8.1. Others Market Analysis & Forecast, 2023-2034 (Revenue, USD Bn)
8. HIV Drugs Market: Distribution Channel Estimates & Trend Analysis
8.1. Distribution Channel Segment Opportunity Analysis
8.2. Hospital Pharmacies
8.2.1. Hospital Pharmacies Market Analysis & Forecast, 2023-2034 (Revenue, USD Bn)
8.3. Drugs Stores & Retail Pharmacies
8.3.1. Drugs Stores & Retail Pharmacies Market Analysis & Forecast, 2023-2034 (Revenue, USD Bn)
8.4. Online Pharmacies
8.4.1. Online Pharmacies Market Analysis & Forecast, 2023-2034 (Revenue, USD Bn)
9. Regional Market Analysis
9.1. Regional Market Opportunity Analysis
10. North America HIV Drugs Market
10.1. North America HIV Drugs Market
10.1.1. North America HIV Drugs Market Size and Forecast, 2023-2034 (Revenue USD Bn)
10.1.2. North America HIV Drugs Market Size and Forecast, By Country, 2023-2034 (Revenue USD Bn)
10.1.3. North America HIV Drugs Market Size and Forecast, By Drug Class, 2023-2034 (Revenue USD Bn)
10.1.4. North America HIV Drugs Market Size and Forecast, By Distribution Channel, 2023-2034 (Revenue USD Bn)
10.2. U.S. Global HIV Drugs Market
10.2.1. U.S. HIV Drugs Market Size and Forecast, 2023-2034 (Revenue USD Bn)
10.2.2. U.S. HIV Drugs Market Size and Forecast, By Drug Class, 2023-2034 (Revenue USD Bn)
10.2.3. U.S. HIV Drugs Market Size and Forecast, By Distribution Channel, 2023-2034 (Revenue USD Bn)
10.3. Canada Global HIV Drugs Market
10.3.1. Canada HIV Drugs Market Size and Forecast, 2023-2034 (Revenue USD Bn)
10.3.2. Canada HIV Drugs Market Size and Forecast, By Drug Class, 2023-2034 (Revenue USD Bn)
10.3.3. Canada HIV Drugs Market Size and Forecast, By Distribution Channel, 2023-2034 (Revenue USD Bn)
11. Europe Global HIV Drugs Market
11.1. Europe Global HIV Drugs Market
11.1.1. Europe HIV Drugs Market Size and Forecast, 2023-2034 (Revenue USD Bn)
11.1.2. Europe HIV Drugs Market Size and Forecast, By Country, 2023-2034 (Revenue USD Bn)
11.1.3. Europe HIV Drugs Market Size and Forecast, By Drug Class, 2023-2034 (Revenue USD Bn)
11.1.4. Europe HIV Drugs Market Size and Forecast, By Distribution Channel, 2023-2034 (Revenue USD Bn)
11.2. Germany Global HIV Drugs Market
11.2.1. Germany HIV Drugs Market Size and Forecast, 2023-2034 (Revenue USD Bn)
11.2.2. Germany HIV Drugs Market Size and Forecast, By Drug Class, 2023-2034 (Revenue USD Bn)
11.2.3. Germany HIV Drugs Market Size and Forecast, By Distribution Channel, 2023-2034 (Revenue USD Bn)
11.3. UK Global HIV Drugs Market
11.3.1. UK HIV Drugs Market Size and Forecast, 2023-2034 (Revenue USD Bn)
11.3.2. UK HIV Drugs Market Size and Forecast, By Drug Class, 2023-2034 (Revenue USD Bn)
11.3.3. UK HIV Drugs Market Size and Forecast, By Distribution Channel, 2023-2034 (Revenue USD Bn)
11.4. France Global HIV Drugs Market
11.4.1. France HIV Drugs Market Size and Forecast, 2023-2034 (Revenue USD Bn)
11.4.2. France HIV Drugs Market Size and Forecast, By Drug Class, 2023-2034 (Revenue USD Bn)
11.4.3. France HIV Drugs Market Size and Forecast, By Distribution Channel, 2023-2034 (Revenue USD Bn)
11.5. Spain Global HIV Drugs Market
11.5.1. Spain HIV Drugs Market Size and Forecast, 2023-2034 (Revenue USD Bn)
11.5.2. Spain HIV Drugs Market Size and Forecast, By Drug Class, 2023-2034 (Revenue USD Bn)
11.5.3. Spain HIV Drugs Market Size and Forecast, By Distribution Channel, 2023-2034 (Revenue USD Bn)
11.6. Italy Global HIV Drugs Market
11.6.1. Italy HIV Drugs Market Size and Forecast, 2023-2034 (Revenue USD Bn)
11.6.2. Italy HIV Drugs Market Size and Forecast, By Drug Class, 2023-2034 (Revenue USD Bn)
11.6.3. Italy HIV Drugs Market Size and Forecast, By Distribution Channel, 2023-2034 (Revenue USD Bn)
11.7. Rest of Europe Global HIV Drugs Market
11.7.1. Rest of Europe HIV Drugs Market Size and Forecast, 2023-2034 (Revenue USD Bn)
11.7.2. Rest of Europe HIV Drugs Market Size and Forecast, By Drug Class, 2023-2034 (Revenue USD Bn)
11.7.3. Rest of Europe HIV Drugs Market Size and Forecast, By Distribution Channel, 2023-2034 (Revenue USD Bn)
12. Asia Pacific Global HIV Drugs Market
12.1. Asia Pacific Global HIV Drugs Market
12.1.1. Asia Pacific HIV Drugs Market Size and Forecast, 2023-2034 (Revenue USD Bn)
12.1.2. Asia Pacific HIV Drugs Market Size and Forecast, By Country, 2023-2034 (Revenue USD Bn)
12.1.3. Asia Pacific HIV Drugs Market Size and Forecast, By Drug Class, 2023-2034 (Revenue USD Bn)
12.1.4. Asia Pacific HIV Drugs Market Size and Forecast, By Distribution Channel, 2023-2034 (Revenue USD Bn)
12.2. Japan Global HIV Drugs Market
12.2.1. Japan HIV Drugs Market Size and Forecast, 2023-2034 (Revenue USD Bn)
12.2.2. Japan HIV Drugs Market Size and Forecast, By Drug Class, 2023-2034 (Revenue USD Bn)
12.2.3. Japan HIV Drugs Market Size and Forecast, By Distribution Channel, 2023-2034 (Revenue USD Bn)
12.3. China Global HIV Drugs Market
12.3.1. China HIV Drugs Market Size and Forecast, 2023-2034 (Revenue USD Bn)
12.3.2. China HIV Drugs Market Size and Forecast, By Drug Class, 2023-2034 (Revenue USD Bn)
12.3.3. China HIV Drugs Market Size and Forecast, By Distribution Channel, 2023-2034 (Revenue USD Bn)
12.4. India Global HIV Drugs Market
12.4.1. India HIV Drugs Market Size and Forecast, 2023-2034 (Revenue USD Bn)
12.4.2. India HIV Drugs Market Size and Forecast, By Drug Class, 2023-2034 (Revenue USD Bn)
12.4.3. India HIV Drugs Market Size and Forecast, By Distribution Channel, 2023-2034 (Revenue USD Bn)
12.5. South Korea Global HIV Drugs Market
12.5.1. South Korea HIV Drugs Market Size and Forecast, 2023-2034 (Revenue USD Bn)
12.5.2. South Korea HIV Drugs Market Size and Forecast, By Drug Class, 2023-2034 (Revenue USD Bn)
12.5.3. South Korea HIV Drugs Market Size and Forecast, By Distribution Channel, 2023-2034 (Revenue USD Bn)
12.6. Australia Global HIV Drugs Market
12.6.1. Australia HIV Drugs Market Size and Forecast, 2023-2034 (Revenue USD Bn)
12.6.2. Australia HIV Drugs Market Size and Forecast, By Drug Class, 2023-2034 (Revenue USD Bn)
12.6.3. Australia HIV Drugs Market Size and Forecast, By Distribution Channel, 2023-2034 (Revenue USD Bn)
12.7. Rest of Asia Pacific Global HIV Drugs Market
12.7.1. Rest of Asia Pacific HIV Drugs Market Size and Forecast, 2023-2034 (Revenue USD Bn)
12.7.2. Rest of Asia Pacific HIV Drugs Market Size and Forecast, By Drug Class, 2023-2034 (Revenue USD Bn)
12.7.3. Rest of Asia Pacific HIV Drugs Market Size and Forecast, By Distribution Channel, 2023-2034 (Revenue USD Bn)
13. Latin America Global HIV Drugs Market
13.1. Latin America Global HIV Drugs Market
13.1.1. Latin America HIV Drugs Market Size and Forecast, 2023-2034 (Revenue USD Bn)
13.1.2. Latin America HIV Drugs Market Size and Forecast, By Country, 2023-2034 (Revenue USD Bn)
13.1.3. Latin America HIV Drugs Market Size and Forecast, By Drug Class, 2023-2034 (Revenue USD Bn)
13.1.4. Latin America HIV Drugs Market Size and Forecast, By Distribution Channel, 2023-2034 (Revenue USD Bn)
13.2. Brazil Global HIV Drugs Market
13.2.1. Brazil HIV Drugs Market Size and Forecast, 2023-2034 (Revenue USD Bn)
13.2.2. Brazil HIV Drugs Market Size and Forecast, By Drug Class, 2023-2034 (Revenue USD Bn)
13.2.3. Brazil HIV Drugs Market Size and Forecast, By Distribution Channel, 2023-2034 (Revenue USD Bn)
13.3. Mexico Global HIV Drugs Market
13.3.1. Mexico HIV Drugs Market Size and Forecast, 2023-2034 (Revenue USD Bn)
13.3.2. Mexico HIV Drugs Market Size and Forecast, By Drug Class, 2023-2034 (Revenue USD Bn)
13.3.3. Mexico HIV Drugs Market Size and Forecast, By Distribution Channel, 2023-2034 (Revenue USD Bn)
13.4. Argentina Global HIV Drugs Market
13.4.1. Argentina HIV Drugs Market Size and Forecast, 2023-2034 (Revenue USD Bn)
13.4.2. Argentina HIV Drugs Market Size and Forecast, By Drug Class, 2023-2034 (Revenue USD Bn)
13.4.3. Argentina HIV Drugs Market Size and Forecast, By Distribution Channel, 2023-2034 (Revenue USD Bn)
13.5. Rest of Latin America Global HIV Drugs Market
13.5.1. Rest of Latin America HIV Drugs Market Size and Forecast, 2023-2034 (Revenue USD Bn)
13.5.2. Rest of Latin America HIV Drugs Market Size and Forecast, By Drug Class, 2023-2034 (Revenue USD Bn)
13.5.3. Rest of Latin America HIV Drugs Market Size and Forecast, By Distribution Channel, 2023-2034 (Revenue USD Bn)
14. MEA Global HIV Drugs Market
14.1. MEA Global HIV Drugs Market
14.1.1. MEA HIV Drugs Market Size and Forecast, 2023-2034 (Revenue USD Bn)
14.1.2. MEA HIV Drugs Market Size and Forecast, By Country, 2023-2034 (Revenue USD Bn)
14.1.3. MEA HIV Drugs Market Size and Forecast, By Drug Class, 2023-2034 (Revenue USD Bn)
14.1.4. MEA HIV Drugs Market Size and Forecast, By Distribution Channel, 2023-2034 (Revenue USD Bn)
14.2. GCC Global HIV Drugs Market
14.2.1. GCC HIV Drugs Market Size and Forecast, 2023-2034 (Revenue USD Bn)
14.2.2. GCC HIV Drugs Market Size and Forecast, By Drug Class, 2023-2034 (Revenue USD Bn)
14.2.3. GCC HIV Drugs Market Size and Forecast, By Distribution Channel, 2023-2034 (Revenue USD Bn)
14.3. South Africa Global HIV Drugs Market
14.3.1. South Africa HIV Drugs Market Size and Forecast, 2023-2034 (Revenue USD Bn)
14.3.2. South Africa HIV Drugs Market Size and Forecast, By Drug Class, 2023-2034 (Revenue USD Bn)
14.3.3. South Africa HIV Drugs Market Size and Forecast, By Distribution Channel, 2023-2034 (Revenue USD Bn)
14.4. Rest of MEA Global HIV Drugs Market
14.4.1. Rest of MEA HIV Drugs Market Size and Forecast, 2023-2034 (Revenue USD Bn)
14.4.2. Rest of MEA HIV Drugs Market Size and Forecast, By Drug Class, 2023-2034 (Revenue USD Bn)
14.4.3. Rest of MEA HIV Drugs Market Size and Forecast, By Distribution Channel, 2023-2034 (Revenue USD Bn)
15. Competitor Analysis
15.1. Company Market Share Analysis, 2023
15.2. Major Recent Developments
16. Company Profiles
16.1. GlaxoSmithKline plc
16.2. F. Hoffmann-La Roche Ltd.
16.3. Gilead Sciences, Inc.
16.4. Merck & Co., Inc.
16.5. AbbVie Inc.
16.6. Teva Pharmaceutical Industries Ltd.
16.7. Boehringer Ingelheim International GmbH
16.8. Bristol-Myers Squibb Company
16.9. Cipla Ltd.
16.10. Johnson & Johnson
16.11. Other Prominent Players
17. Conclusion18. Recommendations

Companies Mentioned

  • GlaxoSmithKline plc
  • F. Hoffmann-La Roche Ltd.
  • Gilead Sciences Inc.
  • Merck & Co. Inc.
  • AbbVie Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Company
  • Cipla Ltd.
  • Johnson & Johnson

Table Information